ストックスクリーナーアプリを入手
697.12
0.11%
1.10
前日終値:
$696.02
開ける：
$697.93
24時間の取引高:
70,295
Relative Volume:
0.08
時価総額：
$76.09B
収益：
$14.20B
当期純損益:
$4.41B
株価収益率:
18.21
EPS:
38.28
ネットキャッシュフロー:
$3.54B
1週間 パフォーマンス:
+3.44%
1か月 パフォーマンス:
+1.31%
6か月 パフォーマンス:
-41.22%
1年 パフォーマンス:
-26.87%
1日の値動き範囲:
$693.07
$699.81
1週間の範囲:
$674.88
$703.14
52週間の値動き範囲:
$642.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
696.54 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.06 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
648.44 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.04 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.15 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea - Korea Economic Daily
Handelsbanken Fonder AB Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Principal Securities Inc. Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Allworth Financial LP Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Everhart Financial Group Inc. Sells 508 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Hussman Strategic Advisors Inc. Purchases Shares of 2,100 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2025-02-20 | Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN) | NDAQ:REGN | Press Release - Stockhouse Publishing
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure ... - The Bakersfield Californian
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN - GlobeNewswire Inc.
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman - TradingView
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Fagan Associates Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before March 10, 2025 to Discuss Your RightsREGN - PR Newswire
Alberta Investment Management Corp Invests $5.06 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rhumbline Advisers Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
842 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Kornitzer Capital Management Inc. KS - MarketBeat
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman - The Bakersfield Californian
ABC Arbitrage SA Buys New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2025-02-19 | Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsREGN | NDAQ:REGN | Press Release - Stockhouse Publishing
US must meet tougher standard in Regeneron kickback lawsuit - Reuters
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-02-19 | Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Class Action: Join by March 10, 2025 – Contact Levi & Korsinsky - The Octant
Callahan Advisors LLC Acquires Shares of 866 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Kestra Investment Management LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Truist Financial Corp Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Principal Financial Group Inc. - MarketBeat
REGN STOCK NEWS: Robbins LLP Reminds Regeneron - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - TradingView
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron Gets Appeals Court to Impose Tougher Kickback Standard - Bloomberg Law
Regeneron Pharmaceuticals, Inc. Securities Fraud Class - GlobeNewswire
Acute Gout Flare Market to Reach New Heights in Growth by 2034, - openPR
Regeneron, Sanofi win FDA review for Dupixent update (REGN) (REGN:NASDAQ) - Seeking Alpha
This Company Just Initiated a Quarterly Dividend: Time to Buy? - MSN
Braun Stacey Associates Inc. Sells 654 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid - Pharmaceutical Technology
CIBC Asset Management Inc Has $24.49 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Montag A & Associates Inc. Sells 644 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) - The Manila Times
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid - GlobeNewswire
Allspring Global Investments Holdings LLC Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Asset Management One Co. Ltd. Has $42.73 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Banque Pictet & Cie SA Buys Shares of 6,312 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Acquired Rep. Julie Johnson - MarketBeat
ROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron Pharmaceuticals, Inc. Investors to ... - The Bakersfield Californian
ROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron - GlobeNewswire
2025-02-17 | Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineREGN | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
0.20%
大文字化:
|
ボリューム (24 時間):